盘点:神药——二甲双胍又有哪些新用处?

2017-08-18 MedSci MedSci原创

二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。这里梅斯小编整理了近期关于二甲双胍新的治疗用处的重要研究进展与大家一同分享。【1】瞄准肿瘤能量源治疗头颈癌在过去的三年里,研究人员发现当患有头颈癌的糖尿病人服用二甲双胍时,其癌症治疗效果比非糖尿病人更好。为

二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。这里梅斯小编整理了近期关于二甲双胍新的治疗用处的重要研究进展与大家一同分享。

【1】瞄准肿瘤能量源治疗头颈癌

在过去的三年里,研究人员发现当患有头颈癌的糖尿病人服用二甲双胍时,其癌症治疗效果比非糖尿病人更好。为了进一步检验二甲双胍与抗癌疗效之间的关系,理解二甲双胍如何改变癌细胞的生物学特征,托马斯杰斐逊大学Sidney Kimmel癌症中心的研究人员对未患糖尿病的癌症病人服用二甲双胍前后的肿瘤细胞进行了检测。结果发现,二甲双胍治疗的病人体内癌细胞凋亡程度显著增加,肿瘤周围的肿瘤相关成纤维细胞也有退化的迹象,表明这些细胞帮助癌细胞生长和转移的能力降低。同时,该研究中病人无高级别的副作用发生。

【2】显著改善HER2阳性早期乳腺癌合并糖尿病患者的预后

临床前研究和既往的临床研究数据均显示二甲双胍有直接和间接的抗肿瘤效应。近期一项荟萃分析结果显示,糖尿病合并乳腺癌患者使用二甲双胍,可以改善患者的总生存和癌症特异性生存。然而这一荟萃分析纳入的研究具有很大的异质性,影响结果的说服力。对于HER2阳性接受辅助抗HER2治疗的早期乳腺癌患者,二甲双胍能否改善糖尿病患者的预后呢?既往尚无研究报道。因此,该探索性分析旨在评估ALTTO研究中,合并糖尿病的早期乳腺癌患者,二甲双胍治疗与否对患者生存解决的影响。结果发现二甲双胍治疗可以改善HER2阳性乳腺癌合并糖尿病患者预后前瞻研究分析,同时也进一步证实了在HER2阳性的患者中,糖尿病患者对比无糖尿病的患者,预后更差。与既往的研究结果相同,二甲双胍的逆转效果,仅限于HR阳性患者;对于HR阴性患者,是否合并糖尿病并不影响患者的生存。

【3】降低结直肠腺瘤复发风险

现有文献表明,最常用的双胍类药物——二甲双胍或能降低结直肠癌(CRC)风险。由于大多数CRCs发病于癌前期病变腺瘤,研究人员在息肉切除术后的2型糖尿病患者中,考察了二甲双胍使用是否降低结直肠腺瘤风险。结果显示,与未接受糖尿病药物的患者相比,只使用二甲双胍与更低的腺瘤复发风险相关,且相关性随二甲双胍总剂量的增加而增强。研究表明,在息肉切除术后的2型糖尿病患者中,二甲双胍使用在降低继发腺瘤方面可能有获益。

【4】预防代谢正常猪缺血性心室颤动

二甲双胍是最常用于治疗2型糖尿病的药物。证据表明,二甲双胍可能会降低2型糖尿病患者的死亡率,但这种作用的机制尚不清楚,二甲双胍治疗无糖尿病患者的疗效尚未确定。如果二甲双胍有利地影响了非糖尿病患者的死亡率,那么它可能具有更广泛的治疗效用。研究人员评估了二甲双胍对代谢正常猪心肌能量和缺血性心室颤动的影响。结果显示,二甲双胍的抗纤维化作用与缺血心肌的动作电位缩短和缺血与非缺血区域之间的动作电位持续时间差异减弱有关。二甲双胍对心肌收缩功能,氧气消耗或葡萄糖或乳酸盐利用率无影响。在临床相关剂量下用二甲双胍慢性治疗代谢正常的猪减少了缺血性VF的死亡率。这种保护与局部缺血时心肌能量的保存有关。缺血期心肌ATP浓度的维持可能会阻止动作电位缩短,再分化的异质性和致死性心律不齐的倾向。研究结果表明,二甲双胍可能对冠心病非糖尿病个体有保护作用。

【5】脆性X染色体综合征的治疗新选择

脆性X染色体综合征(fragile X syndrome ,FXS)是指在Xq27~Xq28带之间的染色体呈细丝样,这一细丝样部位易发生断裂,由此所导致的疾病。二甲双胍能抑制ERK的活性从而抑制缺失X染色体末端的重复翻译,所以有可能减轻患者的临床症状。Nature上最新的一篇报道表明,口服二甲双胍的模型小鼠的社会行为(行为受损或是行为过于活跃)都得到了一定程度的缓解,同时,对小鼠脑组织细胞学分析发现,神经元件的树突棘形态与突触都发生了改变。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 lovetcm

    二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 189****7206

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 戒馋,懒,贪

    超厉害的说

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 Julie W

    二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 Y—xianghai

    学习了新知识

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 忠诚向上

    好好学习看看

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-19 xiaotaiyang1

    看看了解一下,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=235041, encodeId=c51d23504195, content=二甲双胍相当于中医的滋阴类的药物,因此几乎所有阴虚的相关疾病都可以治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Aug 19 09:43:30 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235018, encodeId=b29623501875, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sat Aug 19 09:21:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=235006, encodeId=0d18235006bd, content=超厉害的说, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sat Aug 19 08:50:34 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234998, encodeId=a763234998d4, content=二甲双胍在国内外多种指南中被推举为一线降糖药物。这样推荐的主要理由是该药具有肯定的降糖作用、低血糖风险小、对体重没有不利影响,并且价格较低廉。这些特点使得二甲双胍较其他传统降糖药物具有一定优势。, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Sat Aug 19 08:39:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234983, encodeId=8963234983bd, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sat Aug 19 07:50:57 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234934, encodeId=1af3234934bc, content=好好学习看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Aug 19 07:02:44 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234881, encodeId=8fd2234881ee, content=看看了解一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sat Aug 19 00:14:09 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=234860, encodeId=3b9823486063, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Fri Aug 18 23:29:07 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-18 林3301

    学习学习

    0

相关资讯

Redox Biol:二甲双胍能改善烟草和电子香烟对脑血管系统的危害吗?

电子烟行业在过去几年增长迅速,它没有燃烧,使用电池供电装置来吸入水蒸汽,电子香烟中使用的电子液体尼古丁也可引起OS,脑缺血加剧和继发性脑损伤。而有研究表明,脑缺血损伤前后二甲双胍(MF)治疗能减轻应激并抑制炎症反应。

Diabetologia:二甲双胍预防代谢正常猪缺血性心室颤动

二甲双胍是最常用于治疗2型糖尿病的药物。证据表明,二甲双胍可能会降低2型糖尿病患者的死亡率,但这种作用的机制尚不清楚,二甲双胍治疗无糖尿病患者的疗效尚未确定。如果二甲双胍有利地影响了非糖尿病患者的死亡率,那么它可能具有更广泛的治疗效用。研究人员评估了二甲双胍对代谢正常猪心肌能量和缺血性心室颤动(VF)的影响。

J Gastroen Hepatol:二甲双胍可降低直肠腺瘤风险

研究表明,服用二甲双胍可降低直肠腺瘤风险,特别是对于结直肠肿瘤史和糖尿病等高风险人群

Diabetes Care:生活方式干预、二甲双胍与认知的关系

2002年, 美国糖尿病预防项目研究组(Diabetes Prevention Program Research Group,DPP)花费巨资做了一个多中心大样本随机临床试验来检验生活方式和药物是否可以预防糖尿病, 并且因为效果太好而提前结束而公布,这个研究结果发表在NEJM上,后来又对这些人群进行长期随访观察,陆续发表了一系列研究成果。DDP研究共纳入2280名人群中,平均年龄63.1

J Periodontol:1%二甲双胍凝胶对罹患中/重度慢性牙周炎患者的治疗效果研究:一项临床随机对照试验

这篇研究的目的是为了评估1%二甲双胍(MF)凝胶作为洁治和根面平整术(SRP)的辅助药物治疗中/重度慢性牙周炎的效果。

Diabetes Obes Metab:二甲双胍预防胰岛素治疗2型糖尿病患者体重增加不能用减少能量摄入来解释!

由此可见,二甲双胍预防体重增加不能通过减少能量摄入来解释。